Tarsus Pharmaceuticals Inc (TARS) has a current Price-to-Book (P/B) ratio of 10.23. Compared to its 3-year average P/B ratio of 5.31, the current P/B ratio is approximately 92.86% higher. Relative to its 5-year average P/B ratio of 4.15, the current P/B ratio is about 146.70% higher. Tarsus Pharmaceuticals Inc (TARS) has a Forward Free Cash Flow (FCF) yield of approximately -1.68%. Compared to its 3-year average FCF yield of -9.33%, the current FCF yield is approximately -82.02% lower. Relative to its 5-year average FCF yield of -7.09%, the current FCF yield is about -76.34% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TARS competitors is 3.88, providing a benchmark for relative valuation. Tarsus Pharmaceuticals Inc Corp (TARS.O) exhibits a P/S ratio of 5.30, which is 36.84% above the industry average. Given its robust revenue growth of 128.39%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TARS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TARS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TARS currently overvalued or undervalued?

What is Tarsus Pharmaceuticals Inc (TARS) fair value?

TARS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Tarsus Pharmaceuticals Inc (TARS) is between 68.71 to 385.60 according to relative valuation method.

How does TARS's valuation metrics compare to the industry average?

The average P/S ratio for TARS's competitors is 3.88, providing a benchmark for relative valuation. Tarsus Pharmaceuticals Inc Corp (TARS) exhibits a P/S ratio of 5.30, which is 36.84% above the industry average. Given its robust revenue growth of 128.39%, this premium appears sustainable.

What is the current P/B ratio for Tarsus Pharmaceuticals Inc (TARS) as of Mar 03 2026?

As of Mar 03 2026, Tarsus Pharmaceuticals Inc (TARS) has a P/B ratio of 10.23. This indicates that the market values TARS at 10.23 times its book value.

What is the current FCF Yield for Tarsus Pharmaceuticals Inc (TARS) as of Mar 03 2026?

As of Mar 03 2026, Tarsus Pharmaceuticals Inc (TARS) has a FCF Yield of -1.68%. This means that for every dollar of Tarsus Pharmaceuticals Inc's market capitalization, the company generates -1.68 cents in free cash flow.

What is the current Forward P/E ratio for Tarsus Pharmaceuticals Inc (TARS) as of Mar 03 2026?

As of Mar 03 2026, Tarsus Pharmaceuticals Inc (TARS) has a Forward P/E ratio of 96.15. This means the market is willing to pay $96.15 for every dollar of Tarsus Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Tarsus Pharmaceuticals Inc (TARS) as of Mar 03 2026?

As of Mar 03 2026, Tarsus Pharmaceuticals Inc (TARS) has a Forward P/S ratio of 5.30. This means the market is valuing TARS at $5.30 for every dollar of expected revenue over the next 12 months.

TARS Valuation